Envigo Company Profile

Background

Overview

Envigo is a global contract research organization (CRO) specializing in providing research models and related services to the pharmaceutical, biotechnology, chemical, crop protection, academic, and government sectors. Established in 1931, Envigo has a rich history of supporting scientific research and product development through the supply of high-quality laboratory animals and associated services. The company operates worldwide, with facilities in Europe, the United States, Japan, Korea, and Israel.

Mission and Vision

Envigo's mission is to work together to build a healthier and safer world by providing essential products and research services that support the development of new medicines and the advancement of scientific knowledge. The company's vision is to be the leading provider of research models and related services, enabling researchers to realize the full potential of their critical R&D projects.

Primary Area of Focus

Envigo focuses on supplying a broad range of research-quality animals, including rodents and non-human primates, as well as laboratory animal diets and bedding. These products and services are integral to non-clinical testing and preclinical research, supporting the development and approval of new medicines and other life science products.

Industry Significance

As the second-largest commercial provider of research model products and services globally, Envigo plays a crucial role in the life sciences industry. Its offerings are essential for pharmaceutical and biotechnology companies, contract research organizations, academic institutions, and government agencies engaged in non-clinical research and development.

Key Strategic Focus

Core Objectives

Comprehensive Service Offering: Envigo aims to provide a full spectrum of research models and related services, including genetically engineered models, contract breeding services, and Teklad laboratory animal diets.

Global Expansion: The company seeks to expand its global footprint to better serve its diverse clientele across various regions.

Regulatory Compliance: Ensuring adherence to international standards and regulations is a key focus to maintain the quality and reliability of its products and services.

Specific Areas of Specialization

Research Models: Offering a diverse range of high-quality small and large animal models for basic research and drug discovery.

Laboratory Animal Diets and Bedding: Providing premium Teklad brand diets and bedding solutions tailored to the needs of laboratory animals.

Contract Breeding Services: Offering customized breeding programs to meet specific research requirements.

Key Technologies Utilized

Genetically Engineered Models (GEMS): Developing models with specific genetic modifications to support targeted research.

Animal Health Monitoring: Implementing advanced monitoring systems to ensure the health and well-being of laboratory animals.

Primary Markets Targeted

Pharmaceutical and Biotechnology Companies: Supplying research models for drug discovery and development.

Contract Research Organizations (CROs): Providing models and services for non-clinical testing.

Academic and Government Research Institutions: Supporting fundamental life sciences research.

Financials and Funding

Funding History

Envigo has undergone significant financial developments, including mergers and acquisitions, to strengthen its position in the market. In November 2021, Inotiv, Inc., a leading contract research organization, completed the acquisition of Envigo, integrating Envigo's research models and services into Inotiv's portfolio.

Total Funds Raised

Specific details regarding the total funds raised by Envigo prior to its acquisition are not publicly disclosed.

Notable Investors

Prior to its acquisition, Envigo was privately held, and detailed information about individual investors is not publicly available.

Utilization of Capital

The capital raised and investments made by Envigo were utilized to expand its research model offerings, enhance service capabilities, and support global operations to meet the growing demands of the life sciences industry.

Pipeline Development

Key Pipeline Candidates

As a provider of research models and related services, Envigo does not develop pharmaceutical products but focuses on supplying the necessary models and services to support the development of new medicines and life science products by its clients.

Stages of Clinical Trials or Product Development

Envigo's services are integral to the preclinical stages of product development, providing essential support for non-clinical testing and research.

Target Conditions

The research models provided by Envigo are used in studies targeting a wide range of conditions, including various diseases and health conditions, to support the development of new treatments and therapies.

Anticipated Milestones

Milestones for Envigo are centered around expanding its service offerings, enhancing the quality and diversity of its research models, and strengthening partnerships with clients in the pharmaceutical and biotechnology sectors.

Technological Platform and Innovation

Proprietary Technologies

Genetically Engineered Models (GEMS): Envigo develops models with specific genetic modifications to support targeted research, enabling more precise studies in disease mechanisms and therapeutic interventions.

Teklad Laboratory Animal Diets: Offering premium diets formulated to meet the nutritional needs of laboratory animals, supporting optimal health and research outcomes.

Significant Scientific Methods

Animal Health Monitoring: Implementing advanced monitoring systems to ensure the health and well-being of laboratory animals, which is crucial for the reliability and reproducibility of research results.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed in the available information, Envigo's focus on innovation suggests potential integration of advanced technologies to enhance research model development and service delivery.

Leadership Team

Key Executive Profiles

Dr. Adrian Hardy: President and CEO of Envigo, with extensive experience in the life sciences industry, leading the company's strategic direction and operations.

Dr. Helmut Ehall, DVM, PhD: Senior Vice President, Veterinary Sciences, responsible for overseeing animal welfare and veterinary services, ensuring high standards in animal care.

Jennie Nelson: Production Manager, contributing to the operational excellence of Envigo's facilities and ensuring the quality of research models provided to clients.

Leadership Changes

In November 2021, Inotiv, Inc. completed the acquisition of Envigo, leading to changes in the leadership structure as Envigo became a wholly owned subsidiary of Inotiv.

Competitor Profile

Market Insights and Dynamics

The global market for research models and related services is experiencing growth, driven by increased research and development spending by biopharmaceutical companies. The non-clinical market is expected to grow at a compounded annual growth rate of approximately 7%, indicating a robust demand for research models and associated services.

Competitor Analysis

Charles River Laboratories: A leading provider of comprehensive preclinical and clinical laboratory services, including research models and related services.

Covance: A global contract research organization offering a wide range of services, including research models and preclinical testing.

QPS: A CRO providing comprehensive preclinical and clinical research services, including research models.

Strategic Collaborations and Partnerships

Envigo has engaged in strategic collaborations to enhance its service offerings and expand its market reach. Notably, in June 2019, LabCorp's Covance Drug Development segment acquired Envigo's nonclinical contract research services business, while Envigo acquired LabCorp's Covance Research Products business, resulting in a dedicated organization offering a full range of research models, diets, and bedding.

Operational Insights

Envigo's extensive experience and global presence position it as a significant player in the research model and related services sector. The company's focus on high-quality products, regulatory compliance, and customer service differentiates it from competitors.

Strategic Opportunities and Future Directions

Post-acquisition by Inotiv, Envigo has opportunities to leverage Inotiv's resources and capabilities to enhance its service offerings, expand its global footprint, and continue supporting the development of new medicines and life science products. The combined entity aims to provide a comprehensive suite of nonclinical and analytical services integrated with a wide range of research models, creating a full-spectrum discovery-to-approval solution for drug developers.